Shao-Lee Lin, Acelyrin CEO

Ace­lyrin tops its $250M crossover with new $300M cash raise from blue-chip syn­di­cate

Shao-Lee Lin and her LA-based team at Ace­lyrin are back — and bring­ing its largest fi­nanc­ing haul yet.

The biotech re­port­ed a $300 mil­lion Se­ries C …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.